Invitrocue
Invitrocue is a Singapore-based bio-analytics company that provides personalized cancer drug screening through its Onco-PDO™ patient-derived organoid platform and preclinical CRO services to pharmaceutical, biotechnology, consumer healthcare, and academic clients across Asia, Europe, and Latin America.
- Company typePrivate
- Founded2012
- HeadquartersBukit Merah, Singapore
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What Invitrocue does
Invitrocue is a Singapore-based bio-analytics company founded in 2012 that develops personalized oncology and preclinical drug development services built on a proprietary 3D cell-based scaffolding technology licensed from A*STAR's Agency for Science, Technology and Research. The company's core platform enables the culture of patient-derived organoids (PDOs) from tumor biopsies, which are then used for both clinical drug sensitivity testing via the Onco-PDO™ test and preclinical contract research. Onco-PDO™ is positioned as Singapore's and the world's first clinically validated and approved clinical cancer drug screening service for personalized oncology, with reported 75-80% positive predictive accuracy and over 90% negative prediction rates, validated through peer-reviewed publications in Nature Communications and Nature Medicine.
The company operates a dual business model. The clinical testing stream processes patient tumor samples in laboratories in Singapore, Munich, Hong Kong, and São Paulo with results returned to treating oncologists within 2-3 weeks. The preclinical CRO stream covers drug metabolism and pharmacokinetics, toxicology and safety assessment, hepatocyte services, 3D cell culture, patient-derived organoid services, immunomodulatory assays, customized assays, and humanized mouse models through the Invivocue joint venture. Customer segments span cancer patients and treating oncologists, pharmaceutical and biotechnology firms, consumer healthcare companies, and academic research institutions. The Onco-PDO test is supported across seven solid tumor types (breast, colorectal, lung, ovarian, pancreatic, gastric, and nasopharyngeal cancer).
Invitrocue holds multiple regulatory approvals: Singapore Ministry of Health licensing for Onco-PDO™ (July 2023), CE-IVD certification for Europe, and Thailand FDA approval for the MyTruHealth and MyTruAge DNA methylation test kits acquired through the 2024 Welala acquisition. The parent entity Invitrocue Limited is incorporated in Australia and was previously listed on the ASX (ticker IVQ) before delisting in February 2021; the company now operates as a private entity. Invitrocue maintains wholly-owned subsidiaries across Singapore, Germany, Hong Kong, China, Spain, and Brazil, with a headcount estimated at 11-50 employees, and has pursued an active M&A and partnership strategy in 2024-2026 including the Welala acquisition and an announced merger with Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories.
Invitrocue firmographics
Firmographics- Name
- Invitrocue
- Legal name
- Invitrocue Limited
- Website
- https://invitrocue.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Invitrocue is a Singapore-based bio-analytics company that provides personalized cancer drug screening through its Onco-PDO™ patient-derived organoid platform and preclinical CRO services to pharmaceutical, biotechnology, consumer healthcare, and academic clients across Asia, Europe, and Latin America.
- Ownership category
- akta.pro rank
Invitrocue industry classification
Industry- Product category
- Personalized Oncology and Preclinical CRO Services
- NAICS
- Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA)
- akta.pro secondary industries
- DMPK / ADME & Bioanalysis (HLAGAFAC), Safety Pharmacology (Cardio/CNS/Respiratory) (HLAGAFAB), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where Invitrocue is headquartered
LocationHeadquarters
- HQ city
- Bukit Merah
- HQ country
- Singapore
- HQ region
- Asia
Offices7 records
Markets served
Invitrocue business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Clinical Oncology Testing Services: Revenue generated from Onco-PDO personalized cancer drug screening tests performed for patients. Tests are conducted in company laboratories in Munich (Europe), Hong Kong, and Singapore with results delivered to physicians within 2-3 weeks. The service tests patient-derived organoids against standard-of-care chemotherapeutic drugs.
- Preclinical Contract Research Services: CRO-style services including drug metabolism and pharmacokinetics, toxicology and safety assessment, hepatocyte services, 3D cell culture, patient-derived organoid services, immunomodulatory assays, and customized assays for biotechnology, pharmaceutical, and consumer healthcare companies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing for clinical testing services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Invitrocue product offering
Product offeringCore offering
Invitrocue provides personalized cancer drug screening through its Onco-PDO™ test, which cultures patient-derived tumor organoids and tests them against standard chemotherapy drugs to guide treatment decisions. The company also sells a full suite of preclinical contract research services covering drug metabolism and pharmacokinetics, toxicology and safety assessment, hepatocyte services, 3D cell culture, immunomodulatory assays, customized disease modelling, and humanized mouse models via its Invivocue joint venture.
Product overview
Invitrocue is a personalized oncology and bio-analytics company offering a unified portfolio centered on its Onco-PDO™ phenotype-driven precision oncology drug screening platform, which uses proprietary 3D cell-based scaffolding technology to culture patient-derived organoids for personalized cancer treatment selection. The portfolio includes comprehensive preclinical services encompassing drug metabolism and pharmacokinetics, toxicology and safety assessment, hepatocyte-based assays, 3D cell culture models, immunomodulatory assays, and customized disease modeling services. The company also provides humanized mouse models through its Invivocue joint venture with A*STAR, and offers diagnostic test kits including MyTruHealth and MyTruAge DNA methylation assays. Onco-PDO™ serves as the flagship clinical product, while preclinical services support biotechnology, pharmaceutical, and consumer healthcare companies in drug development.
Differentiator
Problem solved
Functional benefit
Brands
- Onco-PDO: Personalised cancer drug screening test using patient-derived organoids for clinical decision making
- Invivocue
- HiMice
- HepMice
- MyTruHealth
- MyTruAge
Products and services
- Onco-PDO™ A phenotype-driven precision oncology drug screening test that grows a patient's cancer cells as organoids in 3D culture and tests them against standard chemotherapeutic drugs to predict treatment response. Delivered to physicians within 2-3 weeks to guide personalized cancer therapy decisions for patients with breast, ovarian, lung, colorectal, pancreatic, gastric, and head & neck cancers.
- Drug Metabolism and Pharmacokinetics Service
Quantifiable outcome
- 75-80% positive predictive accuracy and over 90% negative prediction rate for Onco-PDO test
- +1 more outcomes
Companies that use Invitrocue
Customer profileSegments4 records
Ideal customer profiles4 records
Invitrocue technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Invitrocue partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core, major and minor.
- XylonixcoreStrategic clinical alliance to validate new method for combating IL-6 pathologies. Xylonix and Invitrocue are collaborating on clinical validation studies for novel therapeutic approaches targeting IL-6 related diseases.
- Angsana Molecular & Diagnostics LaboratorycorePartnership with Angsana and Averywell to advance early lung cancer detection across Asia. Combines Invitrocue's organoid technology with Angsana's molecular diagnostics capabilities.
- Pathnova LaboratoriescoreInvitrocue announces merger with Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories to create expanded diagnostic capabilities.
- GenecastcoreStrategic partnership announced with Genecast. The partnership includes financial advisor appointment for strategic initiatives.
- WelalacoreAcquisition of Welala to create life science leadership in Thailand and ASEAN. Welala brought Thailand FDA approval for MyTruHealth and MyTruAge DNA Methylation Test Kit.
- A*STAR's Genome Institute of SingaporecoreFirst-of-its-kind partnership with A*STAR's Genome Institute of Singapore for the Onco-PDO test. A*STAR is a world-leading research institution in functional genomics and integrative biology. Technology supporting the test has been published in Nature Communications and Nature Medicine.
- Garvan Institute of Medical ResearchmajorResearch collaboration with Sydney's Garvan Institute to progress personalized real-time screening of cancer drugs. Received Human Research Ethics Committee approval for cancer research study.
- National Cancer Centre Singapore (NCCS)majorMOU signed to develop quantitative cancer imaging and radiomics applications for treatment of liver cancer patients (Hepatocellular Carcinoma).
- London School of Hygiene & Tropical MedicineminorCollaboration using 3D in vitro technologies to establish leishmania spp. infection models.
- QIAGEN SuzhouminorStrategic partnership agreement with QIAGEN Suzhou for collaborative development and market expansion in China.
- MundipharmaminorMaster Services Agreement for expansion into in-vitro skin and wound healing assays. Invitrocue developing assays to assess safety and effectiveness of consumer antiseptics and wound dressing products.
- National University Hospital SingaporemajorCollaboration with National University Hospital Singapore for clinical research and validation studies.
- Dr. Chen Qing Feng (A*STAR)coreJoint venture Invivocue formed with Dr. Chen Qing Feng, Principal Investigator at A*STAR Singapore Institute of Molecular and Cell Biology. Dr. Chen's research expertise focuses on humanized mouse models for various disease applications.
Scale indicators7 records
Recent moves11 records
Expansion highlights6 records
Invitrocue competitors and assessment
Company assessmentBroad incumbents
- WuXi AppTec: Global CRO/CDMO with extensive preclinical, DMPK, toxicology, and biologics services, particularly strong in China and Asia. Broad incumbent competing with Invitrocue's Asia CRO footprint and preclinical service menu.
- Eurofins Discovery: Discovery and preclinical CRO services arm of Eurofins Scientific offering in vitro pharmacology, ADME/DMPK, and safety assessment services. Broad incumbent competing across multiple preclinical service lines that Invitrocue offers.
- Charles River Laboratories: Large global CRO with broad preclinical and clinical service offerings including safety assessment, DMPK, and cell-based services. Competes with Invitrocue's preclinical CRO portfolio but at vastly greater scale and breadth.
Emerging players
- SEngine Precision Medicine: Functional precision oncology company using patient-derived 3D models and high-throughput drug screening to identify effective cancer therapies. Comparable niche in the patient-derived functional drug screening market.
- DefiniCDX: Organoid-based diagnostic services company providing functional drug response testing for oncology. Comparable emerging player in patient-derived organoid clinical diagnostics.
Direct peers
- Hubrecht Organoid Technology (HUB): Dutch pioneer in organoid technology and founding institution of the field. Comparable to Invitrocue as a direct organoid technology licensor and service provider to pharma and clinical applications, including oncology drug screening.
- Crown Bioscience: Global preclinical CRO specializing in oncology with extensive PDX and organoid model offerings for drug discovery. Closely comparable to Invitrocue's preclinical CRO services and PDO-based drug screening business.
- Champions Oncology: Oncology-focused company offering PDX and PDO-derived tumor models for translational research and personalized oncology services. Directly comparable in patient-derived oncology model offerings and CRO services.
- InSphero: Swiss 3D cell culture technology company focused on organotypic in vitro models for drug discovery and toxicology. Direct comparable to Invitrocue's 3D cell culture preclinical services; the two are also listed as technology partners.
- Certis Oncology Solutions: Functional precision oncology company providing patient-derived model-based drug sensitivity testing to guide cancer treatment. Comparable to Invitrocue's Onco-PDO clinical testing service targeting oncologists and relapsed patients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Invitrocue social profiles
Digital presenceInvitrocue compliance and trust
Trust signalCompliance4 records
Invitrocue financial estimates
Financial estimateRevenue estimate
Valuation estimate
Invitrocue leadership team
Management profileNumber of profiles
Profiles4 records
Invitrocue subsidiaries and ownership
Company hierarchySubsidiaries7 records
Invitrocue funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Invitrocue M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Invitrocue
What does Invitrocue do?
Invitrocue provides personalized cancer drug screening through its Onco-PDO™ test, which cultures patient-derived tumor organoids and tests them against standard chemotherapy drugs to guide treatment decisions. The company also sells a full suite of preclinical contract research services covering drug metabolism and pharmacokinetics, toxicology and safety assessment, hepatocyte services, 3D cell culture, immunomodulatory assays, customized disease modelling, and humanized mouse models via its Invivocue joint venture.
Is Invitrocue a public or private company?
Invitrocue is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Invitrocue founded?
Invitrocue was founded in 2012. It employs 11 to 50 people.
Where is Invitrocue based?
Invitrocue is headquartered in Bukit Merah, Singapore, in the Asia region.
How does Invitrocue make money?
Two revenue lines are on record. Clinical Oncology Testing Services are the primary driver. The others are preclinical Contract Research Services.
Who are Invitrocue's main competitors?
Broad incumbents on record are WuXi AppTec, Eurofins Discovery and Charles River Laboratories. Emerging players are SEngine Precision Medicine and DefiniCDX. Direct peers are Hubrecht Organoid Technology (HUB), Crown Bioscience, Champions Oncology, InSphero and Certis Oncology Solutions.
Does Invitrocue have an API?
No public API is recorded for Invitrocue.
What industry is Invitrocue in?
Invitrocue's product category is Personalized Oncology and Preclinical CRO Services. Its primary akta.pro industry code is HLAGAFAA, In Vivo Pharmacology (Efficacy/PD Models), with a secondary code of HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 5417 and its SIC code is 8731.